"All truth passes through three stages. First, it is ridiculed, second it is violently opposed, and third, it is accepted as self-evident."
Arthur Schopenhauer, Philosopher, 1788-1860
1) Medizone related posts ONLY..NO other stocks may be mentioned.
2) Keep postings related to Medizone stock . Friendly banter within TOU is acceptable.
3) Limit alerts to whats occuring or potential action...
4) There will be NO attacking a board member for their trading styles regardless of your personal feelings. NO EXCEPTIONS. We are all here to make $$.
5) NO BASHING, PUMPING, HANDWRINGING, CHICKEN LITTLING, TIN FOIL HATS or UNSUBSTANTIATED CLAIMS allowed
6) All IBOX requests/suggestions must be done by PM to a MOD
7) If you have relevant infomation PLEASE back up with a link if available
8) HAVE FUN AND LETS MAKE SOME $$$$
(OTC: MZEI) is a research and development company engaged in developing its AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Following the current laboratory trials, hospital mockup and hospital beta testing will begin. Initial sales are targeted to commence in the 4th quarter of this year.
October 1, 2011 •
New Investor Relations Appointment
October 1st 2011
Communications, both internal and external, are the life-blood of any company... and as we transition further into the commercial phase of our growth, they become even more critical.
With this in mind, I'm delighted to announce a significant step forward in the area of Medizone's Investor relations.
It gives me great pleasure to announce the appointment of a new and valued addition to our team - a highly skilled PR, SEO and web marketing expert from New Zealand - Bruce Smeaton.
Some of you know Bruce already - but what you may not know is that for the past 10 months, he has been directly responsible for raising our company's online profile from total obscurity in the search engines to the point where we now enjoy high rankings in Google for numerous important keywords. His efforts have also resulted in there being more than ten times as many search engine results pages listed in Google (for Medizone-related content) than there were at the same time last year.
The significance of this is two-fold:
Over the coming months we aim to upgrade our website so that we're optimally positioned to field online inquiries and provide a truly professional 'user experience' for our website visitors.
As we gain traction in the search engines for an increasing number of commercially significant search terms it will become proportionately easier for both the media and our target market to find us.
SEO, website management and web marketing aside, it has been Bruce's communication and writing skills that have led to the decision to hire him to manage Medizone's Investor Relations. He originally comes from an ad agency background (senior writer for Ogilvy & Mather) and has been in the PR and Online Marketing arena for over a decade.
Most recently, Bruce was instrumental in securing a key relationship between one of North America's leading social media and news feature placement companies and Medizone, and will be managing it 'going forward'. Watch this space!
I think in closing I'd like to emphasize that Bruce's commitment to all of you in his position as IR Manager, is to respond to your emails and phone calls in a timely, professional and comprehensive manner. NB: The time-zone differential between the US and New Zealand won't be an issue for Bruce as many of his clients are domiciled offshore.
Bruce's role as IR Manager is effective immediately.
The new IR contact details are as follows:
T: 415 331 0202 E: firstname.lastname@example.org
Medizone International Tightens Noose On Food-Borne Pathogens, Bed Bugs and MRSA
September 15, 2011
Following a string of laboratory trial successes with its flagship product, AsepticSure™, Medizone International has filed 3 international patent applications to protect its much-anticipated entry into the global food-processing, bed bugs and sports equipment markets.
San Francisco, CA September 15, 2011. Expanding on its already strong intellectual property protection program, Medizone International, Inc. (MZEI:OB MZEI:QB) has further strengthened its global position under the International Patent Cooperation Treaty. Three refined versions of its US Provisional Applications covering the bed bug, food processing and sports equipment markets, have now been filed.
Medizone's President and Director of Medical Affairs, Dr Michael E. Shannon stated, "The filing of our Insect Infestation Control application reflects a major step forward for Medizone in its insect control program, particularly in the area of bed bug infestation - a world-wide problem which, until now, has been extremely difficult if not impossible to deal with.
"What's most exciting about our recent work is that by modifying our AsepticSure™ protocol, we also destroy larvae and eggs with a single treatment.
"Like the highly resistant spores of bacteria such as C difficile and Bacillus Subtilis, bedbug eggs are very difficult to kill and are often deposited in hard to reach areas. But with our new AsepticSure™ protocol, nothing survives! Hotel and motel rooms, homes, theaters, to mention only a few problem areas, can now be rid of a bedbug infestation in a single treatment with the additional benefit of having any bacterial pathogen simultaneously eliminated.
"Even when dealing with food borne pathogens, nothing can withstand our treatment process. Earlier this year, we announced that our AsepticSure™ system could effectively eliminate well-known pathogens such as Listeria, Salmonella and E coli from a vast array of contaminated surfaces, thereby offering an effective solution to yet another global challenge.
"Contaminated sports equipment will almost certainly become an issue of the past as our system is increasingly adopted by the athletic world. The list of potential applications is, in a word, huge - hence the requirement for new extended patent protection. These new patent applications must therefore be seen as part of an ever growing patent matrix reflecting the growing science of AsepticSure™."
CEO, Edwin Marshall pointed out, "Our technology's capability for the food processing industry has taken a giant leap forward in practicality. The charge time required for any given space to achieve sterilization is linear relative to the size of the space. Because we have now been able to achieve > 6 logs, 100% kill with food borne pathogens using dramatically lower charges of ozone than originally specified, the size of the area treatable with our equipment has expanded. This is commercially significant given the size of typical food processing facilities."
In closing Marshall added, "We have just received a 'Notice of Allowance' from the Canadian Patent Office for our foundational patent, 'Healthcare Facility Disinfecting Process and System with Oxygen/Ozone Mixture' and have taken the final, formal steps in the application process. It typically takes two to three months for the Granted patent to be issued following such steps. Medizone's patent protection program is not only on track, but the strength and expanse of the international reach has increased significantly and should greatly contribute to the value of AsepticSure™ moving forward."
For press information on Medizone, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 ??E: email@example.com
Chairman's Message August 31, 2011
From The Desk Of Ed Marshall:
A very important distinction between AsepticSure™ and its competitors was recently made crystal clear at the FIME Show in Miami: Without question, Medizone's technology not only cleans, but actually disinfects (dare I say, sterilizes) virtually any hospital space, regardless of its size and use.
I can now say, unequivocally, that there's nothing commercially available anywhere in the world which comes even close to AsepticSure™ in terms of bacterial kill.
Dr Dick Zoutman, Professor of Pathology at Queen's University, delivered an excellent presentation at FIME, outlining the unassailable science behind AsepticSure™ and the significance of this technology to attain 100% kill rates on both hard and soft surfaces (NB: something our competitors cannot claim).
As Dr Zoutman explained, in a laboratory setting and given enough time, it's possible to achieve 100% kills with very high levels of hydrogen peroxide. The same can also be achieved with very high levels of ozone. However, in real-world settings, neither of these approaches are practical, as the levels of H2O2 or O3 required to independently achieve such results are highly damaging to electronics and simply not environmentally friendly.
Thus, by themselves, neither O3 nor H2O2 misting systems can provide adequate levels of disinfection in real-world environments.
One of the most unique features of AsepticSure™ is that very low doses of ozone and hydrogen peroxide are combined to produce new (and far more potent) free radicals of the Trioxidane family. This, in turn, enables the previously unobtainable sterilization standard of >6 log (>99.9999%) to be reached on both hard and soft porous surfaces in a short period of time, all without the slightest harm to electronics and/or other infrastructure.
I urge you all - shareholders along with everyone else interested in this ground-breaking technology - to set aside 34 minutes of your time and watch a video of Dr Zoutman's talk at FIME as he presents the unique anti-microbial qualities of AsepticSure™ and its growing relevance as a major player in infection control, worldwide.
AsepticSure™ Launch Produces Sales At FIME!
August 22, 2011
New Generation Disinfection Technology - AsepticSure™ - Generates International Interest and Initial Sales at FIME Medical Purchasing Show in Miami
San Francisco, CA, August 22nd, 2011. Medizone International, Inc. (MZEI:OB) (MZEI:QB) announced today that the introductory launch and subsequent product sales (at FIME) of its AJIC peer-reviewed disinfection, and hospital infection control system - AsepticSure™ - was an unprecedented success.
Medizone's CEO, Edwin Marshall, stated: "Not withstanding the fact that we're delighted to have come away from the Show with two initial orders, one from the US and one from offshore, (with more anticipated), it was an extraordinary three-day event with wide international participation.
Foreign attendees confirmed the unabated spread of hospital-acquired infections in their own countries. The appeal of AsepticSure™ capability was very well received, with one attendee commenting to me, 'this is exactly what I came to the show to look for.'
We now have serious inquires from areas as far reaching as Central and South America, Malaysia, Indonesia, Africa and the Middle East. Based on initial meetings with hospital and government contacts from these regions, it is very clear that they're giving serious consideration to AsepticSure™ - a technology unparalleled in its ability to sterilize rooms in a green and friendly way to the environment and infrastructure."
Marshall added, "With regard to our initial sales success - each order is for a first unit to be delivered during Q1 of 2012 at the FIME introductory price of $75,000 with one-year options for three additional units at the standard price of $95,000 each.
If the options are exercised, this will mean that Medizone will have achieved $720,000 in sales during its first three days of offering this technology.
FIME Attendees clearly recognized the unrivalled disinfection capabilities of AsepticSure™ and the contributions our technology will make to the reduction of human suffering and increases in mortality. Just as importantly, they also recognized that AsepticSure™ should save their organizations vast sums of money due to greatly reduced re-admission and legal costs."
Greatest Threat To Bed Bugs Since Last Ice-Age!
August 10, 2011
International Award-Winning Vapor Mist Technology, AsepticSure™, Poised to Eradicate Bed Bugs from Hotel and Travel Industry, Worldwide
Miami Beach, FL, August 10, 2011. Medizone International, Inc. (MZEI:OB) (MZEI:QB) announced this morning at the FIME Medical Purchasing Show in Miami, that its AJIC peer-reviewed, ICICP award-winning hospital disinfection system, AsepticSure™, has just demonstrated resounding effectiveness against bed bugs.
Medizone's President and Director of Medical Affairs, Dr. Michael E. Shannon stated; "As announced by Dr. Zoutman in his presentation this morning at FIME, we've now conclusively demonstrated that AsepticSure™ is 'more than capable' of killing bed bugs.
Given the unprecedented global resurgence of these hardy, increasingly pesticide-resistant insects, this is an immensely exciting achievement for AsepticSure™, both from a scientific and commercial perspective - and over the next few months our new entomology research program will determine the optimum parameters for maximum efficacy within minimum practical time frames.
It would be fair to say that in view of AsepticSure's already proven and unparalleled capacity for sustained >6 log (99.9999%) microbial kill rates against a vast range of pathogens deadly to humans, we can't help but feel extremely confident in this initial finding and the huge potential it presents.
As of this moment, we have our sights firmly set on meeting the exacting requirements for practical applications for the hotel and travel industry in the months ahead.
It's an absolute certainty now that yet another major market has just opened up for this innovative and benchmark-setting technology (AsepticSure™)."
CEO Edwin Marshall added to Shannon's statement by saying, "To put it into perspective, our only real competitor in what is essentially 'an insecticide-free war against bed bugs', would be the onset of another ice-age! After all, aside from toxic insecticide applications, only extreme heat or cold can effectively kill bed bugs."
Marshall added, "Medizone International's engineering, research and development teams have shown outstanding creative talents in developing AsepticSure™ technology in the most adaptive manner possible. While the government variant (intended for building remediation in the case of biological or chemical attack) contains a number of different components required for the specifics of that application, it appears that the hotel and travel industry variant will require only 'minimal tweaking' of the existing software in the hospital production unit. From an economic standpoint, it doesn't get better than that!"
In conclusion, Marshall summed up by saying, "On the basis of AsepticSure's bed bug test results-to-date, the global hotel and travel industry are going to be able to 'sleep a lot easier' at night in the very near future."
For press information on Medizone, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202?? E: firstname.lastname@example.org
Canada NOW Magazine Publishes AsepticSure Story
July 5, 2011
From The Desk Of Ed Marshall
It is with a growing sense of excitement that I am able to advise shareholders that Medizone's AsepticSure™ disinfection technology continues to gain ever-increasing traction and acceptance within academic and research circles.
Most recently, a journal representing the interests of Canadian universities and their research parks showcased Medizone's AsepticSure technology in an article entitled "Taking On The Silent Epidemic". The Journal, Canada Now, speaks on behalf of the Canadian Association of Research Parks and is dedicated to fostering innovation, commercialization and economic competitiveness in a global economy through collaboration among universities, industry and government.
Thanks to the innovative work conducted at Queen's University by Medizone's research team - and I quote the article directly: "We are moving towards revolutionary ways of beating illness and the answer was under our nose the whole time."
I am very proud of our science team and extremely pleased that their work is being recognized as holding great promise for success by one of the finest academic institutions on this continent.
It has been interesting for those of us involved in bringing this dynamic technology to market, to watch "the competition." The superiority of our product should now be obvious to virtually anyone who chooses to look more closely at published efficacy data; the antimicrobial efficacy of AsepticSure is in a league by itself.
As elucidated in the recent peer reviewed article published in the American Journal of Infection Control and recently recognized by Canada Now, there is no competitive system anywhere that can even come close to AsepticSure in terms of both bacterial kill and speed.
As an example, the manufacturer of one of the finest hydrogen peroxide misting systems claims 4 log kill in 3 hours. By comparison, AsepticSure™ reliably achieves 6 - 7 log kills (100% bactericidal kill) in 90 minutes with no damage to the environment!
December 16, 2010
CHAIRMAN'S CHRISTMAS MESSAGE
What an amazing and interesting year it has been for Medizone. Being part of something as rewarding, globally significant and indisputably pro-humanitarian as Medizone's Asepticsure™ sterilization technology is proving to be quite a journey.
Our original concept of sterilizing hospitals with the anticipated benefit being reduced incidence of hospital acquired infections, largely preventable staph (MRSA) and other infections that now cost greater than 100,000 lives annually in the United States alone, along with millions of lives globally, has grown beyond any expectation we originally envisioned. Where we once saw a global market for hospital sterilization, we now see global industries of pathogen free sterilization processes.
Starting on the hospital side of the house, a first round of sucessful hosptial beta testing was reported at Hotel Dieu Hospital, an ambulatory care teaching and research hospital affiliated with Queen's University in Kingston, Ontario, Canada on October 20th. The next phase of beta testing will begin in early 2011 in conjunction with a bio-medical engineering study that is underway to confirm the safe deployment of the AsepticSure™ technology within all hospital environments. In parallel with the above, as part of our plan towards product launch, final development of the commercial device will commence in early 2011. This commercial device is expected to be fully compliant with both North American and European Union regulatory requirements and intended to facilitate the entry of the device into those markets. We are also in the final stages of identifying our production partner for this aspect of the program. Announcements may be expected around mid- January.
The bio-terrorism countermeasures, clean room sterilization and food industry applications require technology of somewhat different specification and increased scale. For some commercial applications these will not be portable systems, but larger capacity permanently installed units. This has evolved into a fully separate area of development from the hospital specific equipment. The Company is now prepared to accept commercial orders for specialty built units for each of these applications and has communicated as much to interested parties. The interest being shown and the steps forward currently underway, with both government and private industry interests, make it increasingly clear that initial sales likely will come from these areas as we move into an exciting and productive 2011.
Finally, let me address what management and many shareholders perceive as a currently weak share price. From the Home page of the Medizone website please go to stock quotes. On the stock quote page click on Charts, and then pull up a two-year chart of Medizone stock performance. What you will observe is an approximate 800% gain in share price over two years. The bottom trend line indicates a very strong consolidation with a promising upward curve. Given what the Company knows is currently underway and what will be transpiring as we move into 2011, it seems pretty obvious this stock has powerful potential. I ask you, what other companies with this kind of promising future do you own that are up 800% over the past two years?
May everyone enjoy a blessed holiday season and a prosperous New Year.
Edwin G. Marshall
Chairman of the Board
Chief Executive Officer
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures.
This Release may contain certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
SAN FRANCISCO, CA--(Marketwire - 11/18/10) - Medizone International, Inc. (OTCBB: MZEI) (OTCQB: MZEI) announced today that it has entered into a common stock purchase agreement establishing a $10,000,000 equity line with Mammoth Corporation of Lake Zurich, IL. The agreement is for a two-year term. Under the terms of the agreement, Mammoth will purchase the Company's common stock at a 25% discount to the average closing bid price over a five day pricing period, with the funds transfer for the stock purchase to be made to the Company within 24 hours following the last day of the pricing period. The maximum investment limit for any one draw down of the equity line is $500,000 and there cannot be more than two draw downs during any 30-day period. There are no options or warrants associated with this agreement. The Company determines when and how much of the investment commitment it wishes to utilize at any given time.
Edwin Marshall, CEO of Medizone, commented, "Previously, Medizone has traditionally been funded by private placements of restricted securities to accredited investors. Until now this has served the company well as we have managed to secure the revenues needed to move forward with our projects, without having to resort to toxic financing of any kind that would cripple the company in the long term. Until we were approached by Mammoth Corporation, Medizone had never been offered a funding package by an institutional investor that we believed would truly enhance shareholder value and also ensure we had the funds available to increase our cash burn significantly when needed, which is exactly what is needed at this time in order to finalize our various research projects and enter into production with equipment suitable for a number of different market segments. We believe that this $10,000,000 funding commitment in the form of a straight stock purchase, without warrants, options, debt funding or other toxic aspects attached, is monumental for the company and will ensure that Medizone will have the necessary financial resources to substantially complete our research, licensing, final product refinement, and to initiate production and enter a number of markets with AsepticSure™ successfully. The financial capability and reserve created through this funding program should enhance shareholder value now and into the future while mitigating many risk factors otherwise associated with comparable financing transactions."
Brad Hare, President of Mammoth Corporation, added, "Ed and I were introduced by a trusted mutual business associate. When we realized what Medizone has achieved in the area of sterilization technology with the company's lead product AsepticSure™, it immediately became clear to me that this was a rare investment opportunity. In finalizing our due diligence, this commitment to Medizone became an easy decision. I am not only excited about the opportunity Mammoth Corporation has relative to the anticipated financial gain from our investment, it is also wonderful to invest in something so valuable and far reaching for the good of humanity."
As of April 30, 2015, the registrant had 351,334,068 shares of common stock issued and outstanding.
Profile Facts and Share Structure:
Annual Shareholders Meeting Video
Description of Aseptisure, it's capabilities and Business Plan moving forward.
If your are considering investing in Medizone this video is full of exciting news!!!
Medizone International Inc.
4000 Bridgeway, Suite 401
Sausalito, CA 94965
Office: (415) 331-0303
Investor Relations: (415) 331-0202
Shareholder Communications: http://www.medizoneint.com/pressframe.html
Web Site: http://www.medizoneint.com
SEC Filings: http://www.secinfo.com/$/SEC/Registrant.asp?CIK=753772
Press Releases: http://www.medizoneint.com/pressframe.html
Medizone International, Inc., a development stage company, engages in research into the medical uses of ozone. The company is seeking regulatory approval for MEDIZONE, a precise mixture of ozone and oxygen. Its MEDIZONE can be used as a therapeutic drug in humans to inactivate various viruses, and to treat various viral diseases, including human immunodeficiency virus, hepatitis B and C, Epstein-Barr, and herpes and cytomegalovirus, as well as to decontaminate blood and blood products, and to treat pathogenic conditions.
The company also focuses on the process of inactivating lipid-enveloped viruses for the purpose of decontaminating blood and blood products, as well as to assist the treatment of various diseases. In addition, Medizone International develops and acquires the related technology and equipment for the medical application of its Medizone Technology, the company's drug production and delivery system. The company, formerly known as Madison Funding, Inc., was incorporated in 1984 and is headquartered in Stinson Beach, California
*~ Dr. Michael Shannons Credentials ~*
Dr. Michael E. Shannon
Board Member & Director of Medical Affairs
Dr. Shannon received his medical degree from Queen's University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years. He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years. In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General's office. His assignment being to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004. Dr. Shannon then served on a special assignment to the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully held in Toronto in December of 2007.
Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University. Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2002. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed responsibility for medical affairs. In October 2008, he was additionally appointed the President of the Canadian Foundation for Global Health.
As a board-certified physician in preventive medicine, with post-graduate training in internal medicine, infectious diseases, and public health, Dr. St. John has 35 years of experience in the management of medical science for public health programs, legislation, and policy development. During his career, he has developed and managed large and small scale infectious disease control programs in domestic and international environments. Shortly before the 9/11 attacks in the US, he was appointed as a Director-General in the Canadian Department of Health with responsibility for developing Canada's first Centre for Emergency Preparedness and Response for crises and disasters affecting the health of the public. He retired from this position in February 2007.
Dr. St. John began his public health career as a commissioned officer in the US Public Health Service, assigned to the US Centers for Diseased Control and Prevention. Through his work in domestic and international organizations, he acquired an extensive understanding of US Public Health Service institutions, the US and Canadian governments and their states, provinces and territories, the Pan American Health Organization (The World Health Organization's Regional Office for the Americas), the World Health Organization and domestic and international non-governmental and development organizations.
During his tenure with the Canadian Department of Health and subsequently the Public Health Agency of Canada, he rebuilt the Canadian Quarantine Service, co-founded the Global Public Health Intelligence Network (GPHIN - a 24/7 global electronic monitoring system of all infectious disease outbreaks worldwide), modernized the Canadian National Emergency Stockpile System (a national network of strategically placed depots containing emergency medical supplies worth over $300 M) and established the first federal focus for medical counter-terrorism.
Dr. St. John graduated from three distinguished Ivy League Universities (BA from Yale University, MD degree from Columbia University and Masters in Public Health from Harvard University).
Dr. Dick Eric Zoutman
Professor and Chair,
Divisions of Medical Microbiology and of Infectious Diseases, Queen's University
Medical Director of Infection Prevention and Control Services,
University Hospitals Kingston, Kingston, Ontario
Dr. Dick Zoutman has been practicing medicine for over 20 years and specializes in Internal Medicine, Infectious Diseases and Medical Microbiology at Queen's University at Kingston. A primary focus of his investigative work has been understanding the prevention and control of healthcare-associated infections and related medical errors. Using a systems analysis approach to examine healthcare operations, Dr. Zoutman has evaluated antibiotic prescribing and utilization in the community, acute care and long term care sectors. He has shed light on the factors that lead to the over-prescribing of antibiotics in family practice, as well as the failure of hospitals to successfully prevent surgical wound infections by properly prescribing antibiotics to patients undergoing major surgery. Dr. Zoutman continues to examine the impact of hospital resource allocation and infectious adverse events, as well as the use of information systems to improve the quality of patient care and to reduce hospital acquired infections. Dr. Zoutman's work and collaborations have spanned the globe from North America, South America, the Balkans, the Middle East and Africa.
He is Physician-Director of the Board of the Community and Hospital Infection Control Association of Canada. During the 2003 outbreak of SARS in Toronto Dr. Zoutman chaired the Ontario SARS Scientific Advisory Committee responsible for advising the Ontario government on outbreak management strategies.
Dr. Zoutman is Chair of the National Bioterrorism Contingency Task Force for Hospitals; and a member of the Infection Control Guidelines Steering Committee and the Canadian Nosocomial Infection Surveillance Program. Dr. Zoutman is also Chief of the Department of Medical Microbiology and Medical Director of Infection Prevention and Control at the South Eastern Ontario Health Sciences Center in Kingston. Dr. Zoutman is professor of Pathology & Molecular Medicine, of Community Health and Epidemiology, and of Medicine in the Faculty of Health Sciences at Queen's University.
The solution is quite easy in one sense. Just eradicate the infectious diseases from the hospital and the problem is solved. That is prevention. The issue with this prevention is that present methods of cleaning, disinfection and sterilization are not effective. Current cleaning protocols for the sanitization of hospitals have become increasingly ineffective, resulting in an accumulation of deadly bacteria throughout facilities.
Recent research conducted by Microsearch Laboratories demonstrated that, after rinsing and cleaning prior to testing using standard procedures, a cleaning mop collected from a New York hospital was found to have in excess of 150,000 colonies of C. difficile. These results raise concerns about the efficacy of current cleaning and disinfecting procedures.
To make matters even worse, non-medical surfaces, e.g., carpets, bedding and curtains, porous materials in ceilings, once impregnated with highly resistant nosocomial pathogens (in particular, spore formers such as C. difficile) cannot be disinfected with currently available agents and processes. Over time, these pathogens may accumulate in dangerously high concentrations.
Current procedures for the sensitization of hospitals have become increasingly ineffective, resulting in an accumulation of deadly bacteria throughout facilities.
Many people do not realize that ozone had a long and successful history of use as a potent anti-bacterial, anti-fingal and anti-viral agent. Ozone was first used as a disinfectant in 1881 by Dr. Kellog. In 1893 Ozone was used in the Netherlands for water purification. Presently, in excess of 3,000 municipalities around the world use Ozone for water purification.
Research conducted in New York City has also demonstrated that Ozone is effective against Legionella Bacteria, as well as pseudomonas populations in those water purification plants. Ohio State University (2001) demonstrated a 4 log difference in sporicidal action of Ozone vs. Vaporized Hydrogen Peroxide (6.1 log reduction for Ozone vs. 1.6 log reduction for VHP). Microsearch Laboratories has demonstrated (2007) that Ozone is 3,200 times more effective than chlorine.
Medizone International, Inc. Corporate Strategy
Medizone (OTCBB: MZEI) has moved toward product development with lower development costs with the objective of achieving revenue production in the shortest period of time. The focus is in the field of hospital sterilization. This development pathway is based, in part, on a review of published data on hospital-derived infections, an area of rapidly growing concern in the medical community and subject to increasing governmental oversight and regulation on both a state and federal level in the United States and extensive scrutiny in Canada, the UK and Europe.
Medizone's extensive experience with ozone technologies and its bio-oxidative qualities has contributed greatly in pursuing this initiative. Near term efforts have been directed toward one of the Company's founding tenets, namely that under the right conditions, ozone can be extremely effective at sterilizing virtually all biological fluids which includes blood, serum, and plasma and its fractionates, as well as all biologically contaminated equipment and spaces.
Medizone is discovering that its unique ozone generating technologies when combined with other new emerging technologies will play a vital role in addressing what public health officials and surgeons world-wide are beginning to recognize as "The Silent Epidemic" silent epidemic: CA-MRSA and HA-MRSA, Richard P. Evans, MD, American Academy of Orthopedic Surgeons, May 2008, "AAOS Study", in reference to MRSA (methicillin-resistant staphylococcus aureus) infection.
Partnership with Multinational Corporation
Following proof of reliability of the first commercially delivered units, Medizone will have optimized its strengths as a research and development company. It then expects to partner with a large corporation embedded in the hospital sector for increased:
The Canadian Foundation for Global Health (CFGH), an affiliate of Medizone International, was founded under Canadian Federal Law as a not-for-profit Canadian Corporation headquartered in Ottawa, Ontario, Canada.
Michael E. Shannon, M.A.,M.Sc.,MD serves as the President of the Canadian Foundation for Global Health. Dr. Shannon is also the Director of Research for Medizone International and a member of the Medizone Board of Directors.
The Foundation has attracted a broad spectrum of the most highly qualified scientist, infectious disease specialists and other medical health professionals from diverse fields of interest to serve on its Board of Directors, Science Advisory Board and as Principal Investigators.
Medizone's Board of Directors have adopted a business philosophy of "creating a corporate paradigm in which the corporation's profit follows its' social contribution." The establishment of this foundation fits into that paradigm not only by being positioned to attract the highest quality professionals possible to our research projects.
It is envisioned that as Medizone's products and treatments become ready for market, the Foundation may play a vital role as a distribution source for developing countries with varying price breaks depending on the county's needs and the availability of international assistance. We intend to make efforts through both the for-profit and the non-profit sectors to create affordable medical solutions as widely available as possible for the people of the planet.
While the Foundation's current focus remains on the development of the Medizone AsepticSure™ hospital sterilization initiative, we envision that in the future the Foundation may become involved in other projects that may or may not be related to the work of Medizone.